ArticleFrontiers in immunology2026
The effect of amphetamine-type stimulants on immune response in HIV-infected individuals: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The co-occurrence of amphetamine-type stimulant (ATS) abuse and HIV infection is prevalent, yet the impact of ATS abuse history on immune reconstitution in people living with HIV (PLWH) remains uncertain. We aim to assess the impact of ATS abuse history on immune reconstitution in PLWH with low CD4+ levels and high ART adherence. Methods: Using data from China's National Free Antiretroviral Treatment Program and Drug Rehabilitation Management Platform data, we identified PLWH who met the inclusion criteria between 2016 and 2022. Propensity score matching paired participants. Primary outcomes focused on immune response after 2 years of ART, and secondary outcomes including CD4+ T-cell count recovery, net increase in CD4+ T-cell count, CD4+ T-cell growth rate, time to immune response, and AIDS-related mortality. Results: After matching 2,372 PLWH into ATS and non-ATS cohorts, the ATS group exhibited lower immune response rates, delayed responses, smaller increases in CD4+ T-cell counts, and slower initial CD4+ T-cell growth, although growth rates were comparable at later time points. Cox regression analysis identified ATS exposure as an independent risk factor for poorer immune responses 2 years after ART initiation [HR: 0.558 (0.485-0.643), P<0.001]. Kaplan-Meier analysis demonstrated a lower cumulative immune response rate in the ATS group. Longer ATS exposure was associated with reduced immune response rates in PLWH after ART initiation. Conclusions: A history of ATS abuse hinders HIV immune reconstitution, underscoring the need for tailored services for PLWH with ATS exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.